Introduction. The effect of a prolonged oral anti-inflammatory therapy on PSA values in patients with persistent abnormal PSA values after negative prostate biopsy (PBx) was evaluated. Material and methods. From September 2011 to September 2012, 70 patients (median age 62 years), with persistent abnormal PSA values after negative extended PBx, were given an herbal extract with anti-inflammatory activity for 3 months (Lenidase ® ; 1 tablet daily constituted of baicalina, bromelina and escina). All patients were submitted to prostate biopsy for: abnormal DRE; PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA < 25% and < 20%, respectively. Three months after the end of anti-inflammatory therapy all patients were revaluated; indication for repeat saturation biopsy (SPBx) and detection rate for PCa were compared with those previously recorded in our Department using the same inclusions criteria for biopsy. Results. Oral administration of Lenidase ® was well tolerated and no side effects were observed; PSA values decreased in 54 (77.8%) out 70 patients with a median PSA reduction of 20.5% (from 8.8 to 7 ng/mL) and remained unchanged in 16 patients (22.2%); the repeat SPBx rate resulted significantly lower (22.8% vs 35.5%; p < 0.05) showing a superimposable detection rate for PCa (3 cases) in comparison with our previous data (18.7% vs 22%). Conclusions. In our preliminary data a prolonged oral anti-inflammatory therapy reduced PSA levels in patients with negative PBx and persistent suspicious for PCa decreasing the indication to perform repeat SPBx (about 30% of the cases).
INTRODUCTION
The low specificity of PSA test in diagnosing prostate cancer (PCa), especially for serum PSA values < 10 ng/mL is due to spontaneous fluctuation (1) , ejaculation, BPH and acute or subclinical chronic prostatitis (CP). PSA levels have been correlated with the extent and degree of inflammation (2, 3) and a short trial of antibiotics for a likely subclinical CP has some theoretical advantages in decreasing PSA levels (34.6-56% of the cases) (4, 5) thus minimizing the number of biopsies for falsely elevated PSA (20-30% of the cases) (6, 7). The difference between pre and post-treatment PSA levels appears significant only in benign conditions (BPH and prostatitis cases) while in histologically proven ORIGINAL PAPER Does prolonged anti-inflammatory therapy reduce number of unnecessary repeat saturation prostate biopsy? Summary cancer the difference seems unremarkable (8). At the same time, the administration of nonsteroidal antiinflammatory drugs (NSAIDs) or aspirin, blocking the cyclooxygenase (COX) activity (a strong mediator of inflammation), could have a potential role in decreasing PSA values. However, the relationship between oral NSAIDs consumption, PSA levels and PCa risk is unknown (9). In this prospective study we evaluated, in patients with negative extended prostate biopsy and persistent abnormal PSA values, the effect of a prolonged oral antiinflammatory therapy on PSA values in order to reduce the number of unnecessary repeat biopsies.
ously recorded in our Department using the same inclusions criteria for biopsy. Finally, a p value < 0.05 was considered statistically significant.
RESULTS
Oral administration of Lenidase ® was well tolerated and no side effects were observed. Among 70 patients enrolled, PSA values decreased after anti-inflammatory therapy in 54 (77.8%) with a median PSA reduction of 20.5% (from 8.8 to 7 ng/mL) and remained unchanged in the remaining 16 patients (22.2%). Clinical parameters and serum exams before and after Lenidase ® administration are listed in Table 1 . All 16 patients whose PSA did not decrease after therapy underwent repeat SPBx (6 had a PSA included between 4-10 ng/mL and 10 greater than 10 ng/mL) and in 3 of them a cancer was found (all these men had one previous negative biopsy and a PSA > 10 ng/mL). The incidence of repeat biopsy in the patients submitted to anti-inflammatory therapy resulted significantly lower in comparison with our previous data (22.8% vs 35.5%) (p < 0.05), respectively; on the contrary, the detection rate for PCa was superimposable (18.7% vs 22%) at repeat SPBx. IPSS and Q max values were superimposable before and after anti-inflammatory therapy (p > 0.05) ( Table 1) .
DISCUSSION
Repeat prostate biopsy constitutes about 30% of all the procedures with an estimated detection rate for PCa equal, in our experience, to 20% and 6% at second and third SPBx (10), respectively; today, the main goal of any early diagnosis protocol should be to reduce the number of unnecessary SPBx due to false positive PSA levels. The intra-individual (physiological) variation of PSA in men with benign prostate biopsy is equal to 9.5% (12); moreover, many common medications have an effect on serum PSA levels: NSAIDs, thiazide diuretics and statins reduce PSA levels from 6% to 26% and the combination of statins with thiazide diuretics could decrease PSA lev-
MATERIAL AND METHODS
From September 2011 to September 2012, 70 patients (median age 62 years; range: 49-72 years), with previous negative extended prostate biopsy and persistent abnormal PSA values, were given an herbal extract with antiinflammatory activity (Lenidase ® , 1 tablet daily) for 3 months. All patients, 2 months before assuming the herbal extract, underwent prostate biopsy for: abnormal digital rectal examination (DRE); PSA > 10 ng/mL, PSA values between 4.1-10 or 2.6-4 ng/mL with free/total PSA < 25% and < 20%, respectively according to our early diagnosis protocol (10). The biopsy was performed by transperineal approach using a 18 G tru-cut needle guided by a 5-6.5 MHz biplanar transrectal probe (GE Logiq 500 Pro). In case of primary biopsy or repeat saturation biopsy (SPBx) a median of 18 (range [16] [17] [18] [19] [20] [21] and 28 cores (range 26-35) were taken, respectively. The biopsy protocol included a median of 9-12 cores in the posterior zone of each lobe (Apex, Med and Base) plus 2-4 cores on the transition zone in case of SPBx (11). The procedure was performed under sedation and antibiotic prophylaxis. All patients had negative DRE and no-one was symptomatic for acute prostatitis. Patients with previous HGPIN or ASAP were not included; moreover, all patients signed an informed consent form. Clinical parameters of the patients enrolled in the protocol are listed in Table 1 ; 37 (52.8%), 18 (25.7%) and 15 (22.5%) men previously underwent one, two and three negative biopsies, respectively. Fifty-eight (64.5%) patients assumed alpha-blockers; none were currently treated with NSAIDs, aspirin, thiazide diuretic, statins, and 5-alfa-reductase inhibitors. At the end of the 3-months course of therapy and after additional 3 months of wash-out, all patients were revaluated with DRE, total PSA, PSA F/T and routine blood test for liver and kidney function. International Prostate Symptoms Score (IPSS) and Q max before and after anti-inflammatory therapy were recorded. The patients with persistent suspicious for PCa underwent SPBx. The repeat SPBx rate after anti-inflammatory therapy and detection rate for PCa were compared with those previ- Table 1 .
Clinical parameters at baseline and 6 months after anti-inflammatory therapy.
anti-inflammatory therapy reduced PSA levels in selected patients (negative prostate biopsy and persistent elevated PSA values) decreasing the indication to perform repeat SPBx (about 30% of the cases). vs 22%) . Therefore, the significantly reduction of PSA levels in comparison with physiological PSA fluctuations (12) and the absence of reliable criteria to select patients at risk for PCa seems to suggest a prolonged trial of anti-inflammatory therapy before taking any decision in patients with negative prostate biopsy and persistently elevated PSA levels. Our results deserve some considerations. Firstly, the absence of a placebo control group; for our purpose, we used as a surrogate our previously recorded cases. Secondly, it is unknown if PSA reduction is uniquely secondary to the anti-inflammatory activity or is in some way influenced by anti-proliferative effects of baicalina (25); thirdly, PCa incidence is available only in patients whose PSA levels remained unchanged after anti-inflammatory trial (the risk of missing PCa diagnosis in men with decreased PSA is actually unknown). Finally, a greater number of patients and a longer follow up are necessary to confirm our results.
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